This article is more than 5 years old. Information may no longer be current.

VIDEO: BRAF-MEK combination represents ‘important new therapy’ for melanoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Victor Sandor, MD, chief medical officer of Array Biopharma, spoke with HemOnc Today about the FDA’s approval of a two-drug combination for a subset of patients with melanoma.

The agency today approved use of the BRAF inhibitor encorafenib (LGX818, Array BioPharma) and the MEK inhibitor binimetinib (MEK162, Array BioPharma) for treatment of BRAF-mutant advanced, unresectable or metastatic melanoma.

“We believe this represents an important new therapy for patients with BRAF-mutant melanoma,” Sandor told HemOnc Today.

The FDA based the approval on results of the phase 3 COLUMBUS trial. Results presented at ASCO Annual Meeting showed combination therapy with encorafenib and binimetinib significantly improved OS compared with vemurafenib (Zelboraf, Genentech) monotherapy or encorafenib monotherapy.

Read more about the FDA approval on Healio.com/HemOnc.